Strongest evidence
The only outcome with moderate evidence strength is reduced upper respiratory infections. Across 5 of 6 studies (including one meta-analysis and several RCTs), BB-12 showed beneficial effects with a predominantly moderate effect size. The most consistent benefits were seen in healthy infants and young children (0–3 years) and children in early childhood education settings. One study used a dose of 10 billion CFU/day, though other studies did not report the dose.
Mixed or weaker evidence
All other eight outcomes have low or very low evidence strength. For short-chain fatty acid production, all 4 studies reported benefit, but the evidence is mixed because only one meta-analysis included human data (in older adults) and the rest were in vitro. For reduced inflammation, all 4 studies were beneficial but with small effect sizes and no human clinical trials. Reduced antibiotic-associated diarrhea showed contradictory results: two reviews reported benefit but the only RCT found a neutral effect. Improved immune function, improved intestinal barrier function, improved gut microbiota composition, and improved gastrointestinal/ gut health all rely on review articles, in vitro, or animal studies, with no statistically significant findings in most cases.
Effective dose patterns
Only one synthesis reported a specific effective dose: 10 billion CFU/day for reducing upper respiratory infections, based on a single study. Across the remaining syntheses, doses were either not reported or not consistently extractable. No cross-cutting dose pattern can be identified from the available evidence.
Population insights
The most clearly defined benefiting population is healthy infants and young children (aged 0–3 years), particularly in early childhood education settings, for upper respiratory infection outcomes. For antibiotic-associated diarrhea, the only studied population was children prescribed antibiotics for acute respiratory illnesses. Older adults appeared in one meta-analysis for short-chain fatty acids, and mice with acute pancreatitis were the only population in one gut microbiota study. No consistent human population data exists for other outcomes.
Notable caveats
Publication bias is flagged as a concern across multiple syntheses — null-result studies in this area may be less likely to be published or indexed. The majority of syntheses are based on small numbers of studies (3–6) and many rely on narrative reviews rather than primary clinical trials. Only one outcome (reduced upper respiratory infections) includes any RCT evidence with consistent positive results. For outcomes like reduced inflammation, improved immune function, and improved intestinal barrier function, no human clinical trials were available, and evidence comes from in vitro, animal, or review-level sources only.